On a standalone basis, Abbott India's net profit fell 5.11% to Rs 177.14 crore on a 1.58% rise in revenue from operations at Rs 1,095.37 crore in Q3 December 2020 over Q3 December 2019.
Profit before tax (PBT) slipped 5.05% to Rs 237.88 crore in Q3 December 2020 as against Rs 250.55 crore in Q3 December 2019. Total tax expense for the quarter skid 4.88% to Rs 60.74 crore as against Rs 63.86 crore in Q3 December 2019. The Q3 result was declared during trading hours today, 9 February 2021.
Shares of Abbott India rose 0.53% to Rs 14,574.65. Abbott India has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. Its business operations are divided into four business divisions: women's health & gastrointestine, gastroenterology and hepatic care; specialty care; gennext & vaccines, and consumer care.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content